For media enquiries please contact:
0492 817 240
media@painaustralia.org.au
Media Releases
Over-the-counter medicinal cannabis a step toward better pain management
16 DECEMBER 2020
Painaustralia has welcomed the announcement by the Therapeutic Goods Administration (TGA) to down-schedule cannabidiol (CBD) and enable the availability of low-dose CBD over-the-counter (OTC) in pharmacies.
CEO of Painaustralia, Carol Bennett, said changes that provide more accessible and affordable pain management options are necessary. “While the number of people living with pain in Australia rises, there will still be significant gaps in access to, and understanding of, best practice holistic pain management. With the recent restrictions applied to opioids in Australia making pharmacological pain treatments less accessible, the schedule 3 listing of CBD and ready availability in pharmacies will add another drug to the list of available treatments. The major missing piece of the puzzle remains access to effective multidisciplinary treatment, but this move to make low dose medicinal cannabis available over the counter is a welcome increase in options available to people experiencing pain.”
The majority of people who seek medicinal cannabis do so for pain management, and there is growing interest and expectation around the use of these products to treat a range of conditions.
Chronic pain can be debilitating and have adverse effects on work, sleep and relationships. People with chronic pain also commonly experience comorbidities such as depression, sleep disturbance and fatigue. The most effective treatments tend to involve multi-disciplinary care.
“Painaustralia supports current efforts to enable quicker access to medicinal cannabis where it has been correctly prescribed,” said Ms Bennett.
Painaustralia is advocating for the adoption of the National Action Plan for pain management (currently with State and Territory health ministers for endorsement) to ensure a national and holistic policy framework that supports consumers, health professionals and the wider community.
Chair of Painaustralia’s Consumer Advisory Group, Sr Mary-Lynne Cochrane, said that low-dose CBD provides another option for the pain toolkit: “When it comes to chronic pain, there is a need to expand availability of safe and effective treatments as current treatments are not adequate. It won’t be a silver bullet or suitable for all people experiencing chronic pain, but it does expand the range of options that might work for some people,” Sr Cochrane said.
“Steps need to be taken to promote quality use of CBD and all cannabis-derived products given the potential for increased use and greater accessibility. Increasing understanding of pain management and the importance of multi-disciplinary care should also be part of promoting more accessible use of CBD and other medicinal cannabis products.”, Ms Bennett concluded.
16 December 2020
17 November 2020
06 October 2020
21 September 2020
04 August 2020
28 July 2020
07 May 2020
06 February 2020
23 October 2019
26 September 2019
18 August 2019
22 July 2019
17 June 2019
14 June 2019
20 May 2019
09 May 2019
02 May 2019
05 April 2019
04 April 2019
04 April 2019
11 December 2018
7 December 2018
29 November 2018
9 November 2018
25 October 2018
17 October 2018
12 October 2018
27 August 2018
22 July 2018
21 June 2018
20 June 2018
24 May 2018
22 May 2018
21 February 2018
2 February 2018
1 February 2018
25 January 2018
14 December 2017
07 December 2017
04 November 2017
02 November 2017
27 October 2017
27 October 2017
24 October 2017
20 October 2017
18 October 2017
16 October 2017
10 October 2017
07 October 2017
26 September 2017
24 August 2017
08 August 2017
31 July 2017
24 July 2017
31 May 2017
29 May 2017
24 January 2017